A Peek Into The Market Before The Trading Starts
Pre-open movers US stock futures are lower this morning, as investors are awaiting earnings and economic data. Futures for the Dow Jones Industrial Average dropped 16 points to 12,629.00 and S&P 500 index futures fell 2.80 points to 1,340.90. Nasdaq 100 futures dropped 6.75 points to 2,572.50.
A Peek Into Global Markets European markets were mostly lower today. The STOXX Europe 600 Index declined 0.05%, French CAC 40 index fell 0.07%. London's FTSE 100 Index moved down 0.09% and German DAX 30 index dropped 0.01%.
Asian markets ended mixed, with Japan's Nikkei Stock Average dropping 0.24%, China's Shanghai Composite rising 0.24% and Australia's S&P/ASX 200 moving up 0.05%. Hong Kong's Hang Seng index dropped 0.79% and India's Sensex rose 0.24%.
Broker Recommendation Analysts at Citigroup downgraded DeVry (NYSE: DV) from “buy” to “neutral.” The target price for DeVry has been lowered from $40 to $25.
DeVry shares fell 22.35% to $21.40 in after-hours trading.
- Frontier Communications (NASDAQ: FTR) announced today it has signed a wholesale agreement with Hughes Network Systems, LLC (Hughes), the global leader in broadband satellite networks and services. To read the full news, click here.
- China Sunergy Co Ltd (NASDAQ: CSUN) announced today that it had signed a 7.8MW solar module sales contract with Urban Group Energy, the energy arm of Urban Group Australia, one of the top conglomerate companies in Australia. To read the full news, click here.
- Procera Networks (NASDAQ: PKT) today announced a $4.2 million order for more than 100 PacketLogic™ Intelligent Policy Enforcement (IPE) systems that have been deployed by a major U.S. incumbent local exchange carrier (ILEC). To read the full news, click here.
- BioCryst Pharmaceuticals (NASDAQ: BCRX) today announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment. To read the full news, click here.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.